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Azithromycin is a second-generation macrolide anti-
biotic that inhibits the synthesis of bacterial proteins. In 
ophthalmology, azithromycin is used topically in treating 
purulent bacterial conjunctivitis [1] and conjunctivitis caused 
by Chlamydia trachomatis [2,3]. Macrolide antibiotics are 
known for their efficacy in treating acute infections [4]. In 
addition to antibiotic activity, several studies have shown 
that azithromycin could play an anti-inflammatory role. The 
mechanisms of action for the anti-inflammatory properties of 
the macrolides are still being investigated, but they are multi-
factorial and unclear [5]. Anti-inflammatory activity has been 
evaluated in in vivo and in vitro studies that demonstrated 
azithromycin action on several proinflammatory factors. 
Evidence has accumulated over the last few years that part 
of the activity of macrolides is not mediated through their 
traditional antimicrobial effect [6].
Conjunctivitis is an inf lammatory process of the 
conjunctiva and eyelids, and is usually associated with viral 
or bacterial infection [7]. Recently, there has been interest 
in the clinical application of azithromycin in treating infec-
tious and inflammatory processes such as recurrent chronic 
multifocal osteomyelitis [5], asthma [8], cystic fibrosis [9], 
coronary artery disease [9], and concomitant ocular infection 
with Chlamydia pneumonia [10-12].
Early studies on the effect of azithromycin on human 
endothelial cells [13] demonstrated anti-inf lammatory 
effects, independent of its antibiotic action, corroborated by 
studies demonstrating inhibition of proinflammatory factors 
[14]. Azithromycin also decreases transendothelial migra-
tion of neutrophils [15] and monocytes [16] involved in the 
genesis of inflammation [4,6,17]. Consequently, some authors 
suggested that azithromycin could have a potential role in 
treating infectious pathology with an inflammatory compo-
nent, and suggested that this macrolide antibiotic might be 
the therapy of choice for infection-associated inflammation 
[17]. Although current evidence shows that azithromycin 
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Purpose: Macrolide antibiotics are known to have various anti-inflammatory effects in addition to their antimicrobial 
activity, but the mechanisms are still unclear. The effect of azithromycin on inflammatory molecules in the lipopolysac-
charide-induced rat conjunctivitis model was investigated.
Methods: Twenty-four Wistar rats were divided into two groups receiving topical ocular azithromycin (15 mg/g) or 
vehicle. In total, six doses (25 µl) were administered as one dose twice a day for three days before subconjunctival 
lipopolysaccharide injection (3 mg/ml). Before the rats were euthanized, mucus secretion, conjunctival and palpebral 
edema and redness were evaluated. Real-time polymerase chain reaction was used to determine gene expression for 
interleukin-6, cyclooxygenase-2, tumor necrosis factor-α, matrix metalloproteinase (MMP)-2, and MMP-9. Interleukin-6 
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(SPSS v.15.0).
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Conclusions: These results suggest that azithromycin administration ameliorates induced inflammation effects in a rat 
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has beneficial effects in pathologies with an inflammatory 
component, a pathogen was also involved in almost all studies 
[18-21], with the exception of a murine model of corneal 
inflammation induced by thermal cautery [22]. Whether the 
beneficial effects were due to anti-inflammatory, antibiotic, 
or combined actions remains obscure.
The present study employs a model of lipopolysac-
charide (LPS)-induced conjunctivitis in rats not associated 
with pathogens to investigate whether the anti-inflammatory 
properties might be demonstrated independently from 
any active microbial infection. LPS is an outer membrane 
component of Gram-negative bacteria recognized by the 
immune system as a pathogen-associated molecular pattern. 
LPS binds the Toll-like receptor 4/cluster of differentiation 
14 complex on the surface of mammalian cells and activates 
cell signaling pathways to induce expression of inflamma-
tory genes, including interleukin-1b, interleukin-6 (IL-6), and 
tumor necrosis factor-α (TNF-α). Peripheral injection of LPS 
in rodents stimulates cells of the innate immune system and 
increases the production of inflammatory cytokines [6,23].
The hypothesis to be tested is that azithromycin 15 mg/g 
eye drops (Azyter, Laboratoires Théa, Clermont-Ferrand, 
France) attenuate the inflammatory response to subconjunc-
tivally injected LPS in a model of acute conjunctivitis in rats. 
In addition, inflammatory markers were quantified to assess 
genetic, protein, and morphological alterations.
METHODS
Animals and study groups: This study was conducted in 
accordance with the National Institute of Health Animal 
Care and Use Committee protocols, the Association for 
Research in Vision and Ophthalmology Statement for the 
Use of Animals in Ophthalmic and Vision Research, as well 
as the guidelines of the Animal Ethics Committee of the 
University of Navarra. Animals were housed in a 12 h:12 h 
light-dark cycle and were provided food and water ad libitum. 
Fifty-four Wistar rats were divided in two groups; one group 
of 30 rats was set up to determine the maximum time point 
for inflammation, and the second group of 24 rats was used 
to determine the azithromycin anti-inflammatory effect. All 
animals were anesthetized with an intraperitoneal injection 
of ketamine (75 mg/kg, Imalgene 1000, Merial, France) and 
xylazine (10 mg/Kg, Rompun 2%, Carlier, Spain).
To determine the maximum inflammation time point, the 
animals received one subconjunctival injection in each eye of 
30 µl of LPS (from Escherichia coli 055:B5 3 mg/ml; Sigma-
Aldrich Química SA, Tres Cantos, Spain) or saline (NaCl 
0.9%, B Braun España, Barcelona, Spain, control group, n=5) 
using a Hamilton high precision syringe (Gastight 1702LT; 
Hamilton Colorado, Reno, NV; Figure 1). Five animals were 
euthanized, under anesthesia, by cervical dislocation at 1, 
2, 4, 8, and 24 h after injection (groups G1 to G5). Before 
the animals were euthanized, images of ocular inflamma-
tion were obtained (Topcon TRC 50FX camera; Topcon 
Corporation, Tokyo, Japan; Figure 1D), and clinical signs of 
inflammation (mucus secretion, conjunctival and lid edema 
and redness) as reported by other authors [7] were graded by 
three blind independent evaluators.
To determine the anti-inflammatory effects of azithro-
mycin, the rats were divided into two groups of 12 and 
received topical ocular azithromycin 15 mg/g or vehicle 
(Miglyol, Thea Laboratoires, Clermont-Ferrand, France). In 
total, six doses (25 µl) were administered in both eyes as 
one dose twice a day for three days before subconjunctival 
LPS injection (3 mg/ml). Azithromycin was administered 
according to the approved clinical regimen, i.e., twice a day 
for three days (i.e., a total of six drops) with the last drop 1 
h before LPS injection. This results in much higher azithro-
mycin concentration in the conjunctival tissue as after one 
drop there is little azithromycin in conjunctiva [24]. It is 
important to have the “real” clinical concentration to judge 
the impact of this regimen, and as the disease lasts only 24 h 
in this acute model, we had to instill azithromycin before LPS 
induction. If not, the inflammatory phenomenon ends before 
the loading concentration of azithromycin is obtained; thus, 
we could not observe an effect. Six hours post-injection, i.e., 
the time point for maximum inflammation, the animals were 
euthanized as for the previous groups (Figure 2). Conjunctival 
tissues were immediately frozen with dry ice for protein and 
RNA extraction.
Quantitative real-time polymerase chain reaction: Total 
RNA was isolated from rat tissue using the ABI PRISM 6100 
Nucleic Acid PrepStation (Applied biosystems, Life Technol-
ogies, Carlsbad, CA). Subsequently, the quantity and quality 
of purified mRNA were checked with a NanoDrop spec-
trophotometer (NanoDrop Technologies, Montchanin, DE) 
at 260/280. Using the qScript cDNA SuperMix kit (Quanta 
Biosciences Inc., Gaithersburg, MD), 1000 ng of each mRNA 
was reverse transcribed with the following conditions using a 
2720 Thermal cycler: 5 min at 25 °C, 30 min at 42 °C, and 5 
min at 85 °C (Applied Biosystems, Life technologies).
Predesigned and validated gene-specific TaqMan Gene 
Expression assays from Applied Biosystems, Life technolo-
gies were used for quantitative real-time polymerase chain 
reaction (RT–PCR). Every set contained gene-specific 
forward and reverse primers and fluorescence labeled probes. 
Probes span an exon junction and do not detect genomic 
DNA. The PCR reaction volume was 20 µl containing 1 µl 
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cDNA, 10 µl TaqMan 2× Universal PCR Master Mix (Applied 
Biosystems, Life technologies), 1 µl predesigned and vali-
dated gene-specific TaqMan Gene Expression Assay 20× 
(Applied Biosystems, Life technologies), and 8 µl water. The 
ABI Prism 7300 real-time PCR system (Applied Biosystems, 
Life technologies) was used to amplify the five selected genes 
from the inflammation pathway, IL-6, matrix metallopro-
teinase-2 (MMP-2), MMP-9, TNF-α, and cyclooxygenase-2 
(COX-2) in three parallel runs for each sample on a 96-well 
reaction plate with the following protocol: 2 min at 50 °C, 10 
min at 95 °C, and 42 cycles of 15 s at 95 °C, 1 min annealing 
and extension at 60 °C. For further statistical evaluations, the 
level of applied housekeeping gene was used as the endog-
enous control for data normalization. Relative quantifica-
tion studies were made from collected data (threshold cycle 
numbers, referred to as Ct) with 7300 System SDS software 
1.3 (Applied Biosystems, Life technologies). The relative 
quantity of the gene-specific mRNA was calculated with 
DataAssist v2.0.
Figure 1. Results obtained at the 
maximum time point for inflam-
mation. A: Clinical signs score 
obtained by three blind indepen-
dent observers. B and C: Inter-
leukin-6 (IL-6) levels determined 
in conjunctival tissue, control 
versus LPS-treated group and 
control vs. time-course lipopoly-
saccharide (LPS)-treated groups, 
respectively; data are expressed 
as mean±standard error of mean 
(SEM). D: Real time polymerase 
chain reaction (RT–PCR) expres-
sion analysis of cyclooxygenase-2 
(COX-2), IL-6, MMP-2, MMP-9, 
and TNF-α proinflammation genes 
as a function of time in the LPS-
treated group compared to the 
control group; data are expressed 
as log2 (relative quantity [RQ]). 
All data were analyzed with 
SPSS 15.0 software or DataAs-
sist v2.0. (*p<0.05; **p<0.01, and 
***p<0.001 versus control)
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Extraction and determination of total protein concentra-
tion: The extracted conjunctival tissue was homogenized 
on 75 µl phosphobuffer (Sigma-Aldrich Química SA) 
using an Ultra-Turrax (IKA) and centrifuged at 13,000 rpm 
for 20 min at 4 °C. Supernatant was collected and protein 
content determined with Bradford’s method as previously 
described [25]. Bradford s´ method is based on the binding 
of Coomassie Brilliant Blue Reagent (Bio-Rad, Temecula, 
CA), to a protein sample, and comparing this binding to a 
standard curve generated by the reaction of known amounts 
of a BSA standard protein (Sigma). The intensity of the color 
obtained is measured at 595 nm and 450 nm for a more sensi-
tive determination.
Western blotting for nuclear factor-kappa B: Equal amounts 
of conjunctival homogenates (3,5 µg) were subjected to 
western blot as previously described with some modifica-
tions [26]. Briefly, samples were mixed with Laemmli buffer 
(Bio-Rad, Hercules, CA) and boiled for 5 min. Samples were 
separated on 9% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) gels and transferred to a 
Figure 2. Anti-inflammatory effect 
of azithromycin in clinical signs. 
A: Pictures of azithromycin-treated 
eyes and vehicle-treated eyes 
obtained with Topcon TRC 50FX 
camera at 6 h post lipopolysac-
charide (LPS) injection. B: Clinical 
sign scores were obtained by three 
blind independent observers. 
A minimum of ten animals per 
group were included. All data were 
analyzed with SPSS 15.0 software 
(*p<0.05 and **p<0.01 versus 
control)
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nitrocellulose membrane. After blocking with 2% enhanced 
chemoluminescence Advance blocking agent (w/v; GE Health-
care, Fairfield, CT) and 0.1% Tween-20 (w/v) in tris buffered 
saline (TBS) for 1 h at room temperature, membranes were 
exposed to the primary antibody (1:500, antinuclear factor-
kappa B [anti-NF-κB], Santa Cruz Biotechnology Inc., Santa 
Cruz, CA) overnight (at 4 °C) followed by incubation with a 
horseradish peroxidase-conjugated goat antirabbit antibody 
(sc2054; 1:5000, Santa Cruz Biotechnology Inc.). Signals 
were detected with an enhanced chemoluminescence kit 
(ECL-Advance western blotting detection kit, GE Healthcare) 
and signal captured with ImageQuant 400 (GE Healthcare). 
The relative intensities of the immunoreactive bands were 
analyzed by densitometry with ImageQuant TL software (GE 
Healthcare). The loading was verified with Ponceau S red, 
and the same blot was stripped and reblotted with an anti-β-
actin monoclonal antibody (Sigma-Aldrich Química SA) to 
normalize the NF-κB levels. Each assay was repeated at least 
three times to ensure accuracy.
Gelatin zymography assay for matrix metalloproteinase-2 
activity: MMP-2 activity was quantified with gelatin zymog-
raphy on subconjunctival tissue homogenates. Non-reducing 
sample buffer (62.5 mM Tris-HCl, pH 6.8; 10% glycerol; 0.1% 
bromophenol blue) was mixed with 8 µg of total protein from 
homogenate supernatants and electrophoresed directly on 
9% SDS-polyacrylamide gels (SDS–PAGE) containing 0.1% 
gelatin (w/v). After electrophoresis, gels were washed 4 times 
for 20 min at room temperature in a 2.5% (v/v) Triton X-100 
solution to remove excess SDS, transferred to a solution 
(Zymogram development buffer, Bio-Rad), and incubated 
for at least 18 h at 37 °C. Protein fixation was developed by 
incubating the gels for 15 min with 50% methanol/7% acetic 
acid and then washing for 30 min (six times, 5 min each) 
with distilled water. Then the gels were stained for 1 h with 
GelCode Blue Stain Reagent (Pierce, Rockford, IL), counter-
stained with distilled water, and analyzed with ImageQuant 
TL software (GE Healthcare) after densitometric scanning 
of the gels. The active MMP-2/(active MMP-2+proMMP-2) 
intensity ratio was designated the MMP-2 activation ratio. 
Each zymography assay was repeated at least three times to 
ensure accuracy.
Interleukin-6 determination with enzyme-linked immunosor-
bent assay: IL-6 levels were determined with enzyme-linked 
immunosorbent assay (ELISA; PeproTech, Rocky Hill, NJ, 
and Gen Probe, San Diego, CA, respectively) following 
manufacturers’ instructions. Equal quantities of total protein 
were used. Data are expressed on ng/µg of total protein for 
IL-6.
Tissue processing for histological analysis: Immediately after 
euthanasia, conjunctival tissue was extracted and processed 
for histology. Briefly, tissue was fixed in Davidson’s solu-
tion (10% Glacial acetic acid, 30% ethanol [95%], and 20% 
formaldehyde [4%]) for 24 h and then in formaldehyde 4% for 
24 h, followed by dehydration with a graded series of alcohol 
and paraffin embedded.
Periodic acid-Schiff staining, conventional staining, and 
measurement of area of mucus secretion: Mucus secretion 
by goblet cells in the conjunctival epithelium was studied 
with periodic acid-Schiff (PAS), a specific technique for 
mucopolysaccharides. Four eyes of each group (azithro-
mycin and vehicle treated) were fixed in Davidson’s solu-
tion as described above. Paraffin-embedded tissue was then 
subjected to microtomy, and 3 μm slides were obtained and 
exposed to conventional PAS staining to evaluate morpho-
logical changes. The mucin secretion stains purple, and 
the nuclei stains blue. Areas of mucopolysaccharides were 
measured by three independent observers in 40X photog-
raphy by using Adobe Photoshop 7.0 lace and histogram tools 
in two PAS-stained samples of each animal. Areas data are 
presented as pixels (mean±standard error of the mean [SEM]) 
and are shown in Table 1.
Determination of inflammatory cell infiltration with immu-
nohistochemistry and immunofluorescence: It is important 
to determine inflammatory cell infiltration into the damaged 
area; immunohistochemical analysis for cluster of differen-
tiation (CD)4+ T cells as well as immunofluorescence for 
CD68 (specific marker for macrophages) localization was 
performed.
Paraffin-embedded conjunctival tissue sections were 
subjected to blocking of endogenous peroxidase activity. 
Macrophages were detected with indirect immunofluores-
cence. Antirat CD68 (AbDSerotec, Dusseldorf, Germany) 
was used as the primary antibody (1:100 diluted in phosphate 
buffered saline (PBS) without calcium and magnesium from 
Sigma-Aldrich, D8537, in goat normal serum 1:20) and goat 
antimouse Alexa Fluor 488 (Molecular Probes, Paisley, UK) 
as the second antibody (1:200 in PBS). Vectashield Mounting 
Media (Vector Laboratories, Peterborough, UK) with 
4’,6-diamidino-2-phenylindole (for nuclear staining) were 
used. Then samples were visualized under a fluorescence 
microscope with appropriate filters for correct visualization.
Statistical analysis: Values are reported as mean±SEM. 
Statistical significance was evaluated with analysis of vari-
ance (ANOVA) or Kruskal–Wallis test to determine the 
maximum time point for inflammation and the Student t 
test or the Mann–Whitney U-test to assess the anti-inflam-
matory effect of azithromycin. After a significant ANOVA 
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or Kruskal–Wallis test, comparisons between groups were 
made with the Bonferroni post-hoc or Mann–Whitney U-test, 
respectively. Statistical significance was accepted at the 
95% confidence level (p<0.05), and analysis was performed 
by using the computer program SPSS (v. 15.0, SPSS Inc. 
Chicago, IL). DataAssist v 2.0 (Applied Biosystems) was 
used for gene expression quantitative analysis. Histological 
analyses for grading, cell counting, and area measurement 
were performed by three blind independent investigators, and 
the results obtained are shown in Table 1 (mean±SEM). All 
data are expressed as the treatment means±SEM.
RESULTS
Maximum time point for inflammation:
Clinical signs—To establish the time point for maximum 
inflammation, clinical signs and IL-6 levels were evaluated. 
The analysis of clinical sign scores (Figure 1A) obtained from 
independent observers showed significant differences in the 
ANOVA test between the control group and groups G1–G5 
for conjunctival redness, conjunctival edema, and mucus 
secretion (p=0.049, p=0.039, and p=0.0001, respectively). 
Comparisons of each group to the control group showed a 
peak of inflammation in groups G3 and G4 (i.e., 4 and 8 h 
after LPS injection), with significant differences in conjunc-
tival redness (p=0.024 and p=0.030, respectively), conjunc-
tival edema (p=0.020 and p=0.013, respectively), and mucus 
secretion (p=0.069 and p<0.001, respectively).
Interleukin-6 determination with enzyme-linked 
immunosorbent assay—IL-6 levels were almost doubled 
by LPS (p=0.033) as averaged from pooled individual values 
of all G1 to G5 animals (Figure 1B). Moreover, IL-6 levels 
were significantly higher in animals euthanized 4, 8, and 24 
h (p=0.014, p=0.024 and p=0.004, respectively) after LPS 
injection (Figure 1C).
Quantitative real-time polymerase chain reac-
tion—The quantitative real time polymerase chain reaction 
expression analysis of inflammation-involved genes showed 
significant differences in groups G2, G3, and G4 in several 
genes compared to the control group (Figure 1D). The TNF-α 
gene, one of the principal genes involved in activating the 
inflammation pathway showed a significant increase at early 
time points (G1, p=9×10−4; G2, p=6×10−4; G3, p=0.014). Simi-
larly, the expression of COX-2 and IL-6 genes underwent a 
significant increase at intermediate time points G2 (p=0.049 
and p=0.042, respectively), G3 (p=0.005 and p=0.017, 
respectively), and G4 (p=0.019, only in IL-6). Meanwhile, 
the analysis of the MMP-9 gene showed significant activation 
only at late time points (G4, p=0.011; G5, p=0.001). MMP-2 
gene expression did not reach statistical significance.
Since most of the genes and protein levels were signifi-
cantly higher between 4 and 8 h, 6 h was selected as the point 
of maximum inflammation and used for the subsequent 
evaluation of the azithromycin anti-inflammatory effect.
Anti-inflammatory effect of azithromycin:
Clinical signs—The analysis of clinical sign scores 
comparing the azithromycin-treated group with the vehicle-
treated group (Figure 2A,B) showed a significant decrease in 
all parameters: redness and edema, both conjunctiva and lid 
(p=0.034; p=0.024; p=0.023 and p=0.003, respectively), and 
the mucus secretion score (p=0.015).
Interleukin-6 determination with enzyme-linked 
immunosorbent assay—To determine IL-6 levels as a marker 
of inflammation, ELISAs were performed on conjunctival 
tissue homogenates (Figure 3A). The azithromycin group 
showed a statistically significant reduction in IL-6 levels 
(p=0.043) compared to the vehicle group.
Western blot analysis of nuclear factor-kappa B—
Western blot for NF-κB in conjunctival homogenates revealed 
significantly less NF-κB (p=0.009) expression in the azithro-
mycin than in the vehicle group (Figure 3B).
Quantitative real-time polymerase chain reaction—
Regarding RT–PCR gene expression analysis, there were no 
significant differences in any of the studied genes between 
the azithromycin-treated group and the vehicle-treated group 
(Figure 3C). However, the MMP-2 and MMP-9 genes showed 
nearly significant reduction in expression in the azithromycin-
treated group (p=0.061 and p=0.100, respectively).
Gelatin zymography of matrix metalloproteinase-2 
activity—Figure 3D shows zymographs for MMP activity 
that demonstrate a statistically significant reduction (p=0.018) 
in MMP-2 activity in the animals treated with azithromycin 
compared with the vehicle-treated animals.
Morphological evaluation of tissue sections and mucus 
secretion assessed with periodic acid-Schiff staining: After 
the tissue sections were processed for histology, images 
were analyzed for correlation of biochemical changes with 
morphologic alterations. Results are summarized in Table 1.
Figure 4A shows PAS staining in conjunctival sections 
demonstrating a clear reduction in mucopolysaccharide 
production by goblet cells in the azithromycin- vs. vehicle-
treated animals. Moreover, the area of mucus in the vehicle-
treated animals was significantly larger (p<0.05) than in the 
azithromycin-treated group, as shown in Figure 4B.
Determination of inf lammatory cells infiltration with 
immunohistochemistry and immunof luorescence: 
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Immunofluorescence for CD68, a marker of macrophage 
infiltration, showed a statistically significant (p<0.05) reduc-
tion of the number of CD68 positive cells in the animals 
treated with azithromycin versus the control animals (Figure 
5A,B).
DISCUSSION
The present study is the first to demonstrate the anti-
inflammatory effect of azithromycin in a rat model of acute 
conjunctivitis induced by LPS. A reduction in inflammatory 
clinical signs, gene and protein expression of several proin-
flammatory molecules (such as IL-6, MMP-2 activity, and 
NF-κB), and macrophage infiltration in damaged tissue as 
well as a reduction in conjunctival mucus area were observed.
In addition to antibiotic activity, azithromycin also 
possesses anti-inflammatory activity [27], though relatively 
weak compared to glucocorticoids. However, azithromycin 
can achieve much higher tissue concentrations, has a long 
tissue half-life at clinical doses, and has fewer adverse effects 
than corticoids [28,29]. Consequently, this antibiotic may 
have utility for certain inflammatory ocular surface diseases 
[29].
Pharmacokinetic studies have confirmed the avail-
ability of azithromycin in tears, conjunctiva, and cornea 24 
h after a single instillation and twice-daily instillation for 
three days of 1.50% azithromycin in the rabbit eye [24]. 
Such findings permit the hypothesis that the effect observed 
in the conjunctiva is caused by azithromycin. The clinical 
signs data obtained in the present study demonstrate that 
azithromycin was able to significantly reduce inflammatory 
signs following LPS injection. Lid and conjunctival redness 
and edema and mucus secretion were less severe in animals 
treated with azithromycin compared with those given vehicle, 
suggesting that azithromycin as well as other macrolides [30] 
are able to prevent clinical alteration signs of inflammation 
as observed in experimental models of corneal refractive 
surgery [11], uveitis in rabbits [31] and humans [4,17,21,23].
Figure 3. Biochemical analysis 
of azithromycin treatment group 
versus control group. A: Inter-
leukin-6 (IL-6) levels are expressed 
as ng/µg of total protein in conjunc-
tival tissue. Azithromycin treatment 
reduced IL-6 levels in conjunctival 
tissue. B: Measurement of nuclear 
factor-kappa B (NF-κB) expres-
sion in conjunctival tissue. Bars 
represent mean±SEM. β-actin was 
blotted as an internal control. C: 
Real time polymerase chain reac-
tion (RT–PCR) expression analysis 
of cyclooxygenase-2 (COX-2), IL-6, 
MMP-2, MMP-9, and TNF-α proin-
flammation genes in the azithro-
mycin-treated group. Change is 
relative to the vehicle-treated group 
(reference). Data are expressed as 
log2(RQ). D: Representative zymo-
gram showing MMP-2 activity and 
the results shown as percentage 
of the azithromycin-treated group 
versus the vehicle-treated group. 
Bars represent mean±SEM. A 
minimum of ten animals per group 
were included. All data were 
analyzed with SPSS 15.0 software 
or DataAssist v2.0. (*p<0.05 versus 
vehicle).
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These clinical signs results agree with those obtained 
for protein expression; IL-6 levels were higher in animals 
with LPS compared with the control animals, and azithro-
mycin reduced IL-6 levels after topical administration for 
three days following LPS. We have also demonstrated that 
azithromycin inhibits LPS-induced NF-κB activation in this 
model, suggesting an anti-inflammatory effect of topical 
azithromycin. Macrolides inhibit the production of many 
proinflammatory cytokines, such as IL-1, IL-6, IL-8, and 
TNF-α, perhaps by suppressing the transcription factor 
NF-κB or activator protein-1 [5]. MMP-2 activity is reduced 
after topical administration of azithromycin compared to 
controls, suggesting that azithromycin has an important 
inhibitory role in synthesizing and degrading extracellular 
matrix. Proteolysis could be increased by LPS with subse-
quent tissue damage. After azithromycin, degradation of 
Figure 4. Mucus secretion analysis 
in conjunctival tissue. A: Peri-
odic acid-Schiff (PAS) staining 
in slides of vehicle (upper) and 
azithromycin (lower). Azithro-
mycin showed a reduction in mucin 
secretion (purple) compared with 
vehicle-treated animals. Magnifi-
cation: 40X. B: Results obtained 
for measurements performed in 
PAS-stained sections. Data are 
represented as mean±standard 
error of mean (SEM). Four eyes per 
group were included. All data were 
analyzed with SPSS 15.0 software. 
(*p<0.05 versus vehicle)
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extracellular matrix could diminish as observed in vitro in 
fibroblasts [32]. Furthermore, researchers have demonstrated 
that azithromycin suppresses expression of matrix metallo-
proteinases in human corneal epithelial cells stimulated by 
zymosan [33]. Moreover, in vivo studies using carrageenan 
and in vitro murine macrophages stimulated with LPS show a 
reduction in the generation of some mediators and cytokines 
involved in the inflammatory process, such as arachidonic 
acid metabolites, nitric oxide, TNF-α , interleukin-1b, and 
IL-6 [23].
Gene expression analysis showed no significant differ-
ences between the azithromycin-treated animals and the 
vehicle-treated animals. However, MMP-2 and MMP-9 
expression was almost significantly reduced by azithromycin. 
However, mRNA expression is first induced and lasts for a 
short period, and protein expression is subsequently induced. 
This means that effects at the gene expression level in this 
rat model are more difficult to demonstrate than those at the 
protein level.
Figure 5. Macrophage infiltration 
analyzed in conjunctival tissue. 
A: Cluster of differentiation 68 
(CD68) positive cells in slides of 
vehicle (upper; magnification: left 
5X, right: 40X) and azithromycin 
(lower; magnification: left 5X, 
right: 40X). The azithromycin-
treated group showed a decrease 
in the number of macrophages 
compared with the vehicle-treated 
animals. CD68 (macrophages): 
green; 4’,6-diamidino-2-phenyl-
indole (nuclei): blue. B: Results 
obtained for counting of CD68 
positive cells in immunofluores-
cence slides. Data are represented 
as mean±standard error of mean 
(SEM). Four eyes per group were 
included. All data were analyzed 
with SPSS 15.0 software. (*p<0.05 
versus vehicle).
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Mucin production has been widely related to inflamma-
tory pathologies such as asthma and bronchitis, suggesting 
an important role of these proteins in the establishment and 
progression of disease. Goblet cells in the normal conjunctiva 
are empty of mucus and secrete mucins to protect the eye. 
Moreover, chronic inflammatory diseases such as allergic 
conjunctivitis and early dry eye lead to increased goblet cells’ 
mucin secretion into tears and ocular surface [6,34,35]. The 
clinical signs (mainly mucus production) in the present study 
prompted determination of mucopolysaccharides production 
by goblet cells in conjunctival tissue slides with PAS staining. 
However, researchers have demonstrated that in inflam-
matory pathologies, e.g., bronchiectasis, there is excessive 
mucus secretion by goblet cells. The present study showed an 
increase in mucus production in the conjunctival tissue of the 
control animals versus the animals treated with azithromycin, 
suggesting that azithromycin seems to play an important role 
in reducing mucus secretion by conjunctival goblet cells [35].
Another important finding of this study is that azithro-
mycin reduced the infiltration of inflammatory cells (macro-
phages) into areas of damage. An important aspect of inflam-
mation is extravasation of neutrophils and inflammatory cells 
into the tissues; macrolides block formation of the adhesion 
molecules necessary for cell migration [5]. Macrophages 
are versatile cells intimately involved in all aspects of the 
immune response and the complex process of inflammation 
[16]. The decrease in the number of macrophages in this study 
agrees with observations at the gene and protein levels, as 
well as with clinical signs graded in a previous study. The 
study demonstrates that azithromycin decreases production 
of mucus by epithelial cells and biosynthesis of proinflam-
matory cytokines from macrophages and epithelial cells by 
inhibiting NF-κB [6]. Moreover, other authors have shown 
that inhibition of LPS-induced pulmonary neutrophilia and 
IL-1β concentrations in the lung are mediated through effects 
on alveolar macrophages [36] and inhibition of the in vitro 
production of IL-6, IL-8, and macrophage inflammatory 
protein-2 by human monocytes [6].
In conclusion, we have examined the effects of azithro-
mycin on the LPS-induced acute conjunctivitis model in rats, 
and we found evidence that topical azithromycin inhibits 
the expression of inflammatory cytokines such as IL-6, 
MMP-2 activity, and NF-κB. Moreover, topical administra-
tion of azithromycin reduces the effects of acute inflamma-
tion such as mucus secretion and macrophage infiltration. 
Azithromycin could be a good alternative to corticoids to 
solve inf lammation-derived alterations. Macrolides, far 
beyond their traditional antimicrobial properties, possess 
considerable anti-inflammatory properties, corroborated in 
the present study in an acute model of conjunctivitis. These 
results suggest that azithromycin is a promising agent for 
treating ocular surface inflammation in its clinical indica-
tions of non-bacterial conjunctivitis.
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